Latest Breaking News On - Liz melone - Page 6 : comparemela.com
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Aileron Therapeutics Reports Second Quarter 2021 Financial
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
REDWOOD CITY, Calif., Jan. 11, 2021 Seer (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today that they have signed a non-exclusive commercial agreement with Bruker Corporation, one of the world’s leading analytical instrumentation companies. This agreement will enable Seer to market the timsTOF Pro mass spectrometer system together with its Proteograph Product Suite. The combined product offering provides customers with a complete and scalable workflow for unbiased, deep, rapid and large-scale proteomics – making proteomics more accessible to a broader range of customers, including those interested in adding proteomics to their genomics and multi-omics studies.
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
January 05, 2021 21:55 ET | Source: NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc. South San Francisco, California, UNITED STATES
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the pricing of an underwritten public offering of 4,629,630 shares of its common stock at a price to the public of $27.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NGM. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions. In connection with the offering, NGM h